GMED vs IDXX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 13, 2026

GMED

42.3
AI Score
VS
GMED Wins

IDXX

37.5
AI Score

Investment Advisor Scores

GMED

42score
Recommendation
HOLD

IDXX

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GMED IDXX Winner
Revenue 1.55B 2.36B IDXX
Net Income 275.87M 616.86M IDXX
Net Margin 17.8% 26.2% IDXX
Operating Income 332.82M 788.15M IDXX
ROE 5.8% 38.3% IDXX
ROA 5.0% 17.9% IDXX
Total Assets 5.49B 3.44B GMED
Cash 507.75M 196.93M GMED
Current Ratio 4.62 1.17 GMED
Free Cash Flow 339.32M 556.78M IDXX

Relative Price Performance (Last 90 Days)

GMED 1M: -13.4% · 3M: -7.9% IDXX 1M: -11.5% · 3M: -9.5%

Current Technical Phase

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 32

RSI (14): 31.6 · Price: $74.19

IDXX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 32

RSI (14): 31.5 · Price: $504.70

Fundamentals Snapshot

Metric GMED IDXX
Market Cap
Forward P/E 13.7 30.2
Trailing P/E 19.1 36.2
Revenue (TTM)
Revenue Growth 0.1% 0.1%
Gross Margin 0.7% 0.6%
Operating Margin 0.2% 0.3%
EPS 3.86 13.98
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, GMED is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.